Technical Analysis for EARS - Auris Medical Holding AG
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Up | Down |
| Historical EARS trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Fell Below 20 DMA | Bearish | 0.00% | |
| 1,2,3 Pullback Bullish | Bullish Swing Setup | 0.00% | |
| Non-ADX 1,2,3,4 Bullish | Bullish Swing Setup | 0.00% | |
| Calm After Storm | Range Contraction | 0.00% | |
| Narrow Range Bar | Range Contraction | 0.00% | |
| NR7 | Range Contraction | 0.00% | |
| MACD Bearish Signal Line Cross | Bearish | -3.01% | |
| 20 DMA Support | Bullish | -3.01% | |
| 1,2,3 Pullback Bullish | Bullish Swing Setup | -3.01% | |
| Non-ADX 1,2,3,4 Bullish | Bullish Swing Setup | -3.01% |
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 03/19/2020
- Sector: Healthcare
- Industry: Biotechnology
Auris Medical Holding AG, a clinical-stage biopharmaceutical company, focuses on the development of novel products for the treatment of inner ear disorders. Its lead product candidate includes AM-101, which is in Phase III clinical trials for treating acute inner ear tinnitus. The company is also developing AM-111 for the treatment of acute sensorineural hearing loss, as well as for Meniere diseases; and other development programs comprising AM-102 and AM-123 that are in preclinical studies. It has a collaboration and license agreement with Xigen S.A. to develop, manufacture, and commercialize pharmaceutical products, and drug delivery devices and formulations for the treatment of inner ear disorders. The company was formerly known as Auris Medical AG and changed its name to Auris Medical Holding AG in April 2014. Auris Medical Holding AG was founded in 1998 and is headquartered in Zug, Switzerland.
Biopharmaceutical Pharmaceutical Products Drug Delivery Nervous System Perception Hearing Loss Auditory System Drug Delivery Devices Ear Hearing Sensorineural Hearing Loss Tinnitus
Biopharmaceutical Pharmaceutical Products Drug Delivery Nervous System Perception Hearing Loss Auditory System Drug Delivery Devices Ear Hearing Sensorineural Hearing Loss Tinnitus
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 3.2 |
| 52 Week Low | 0.65 |
| Average Volume | 238,986 |
| 200-Day Moving Average | 1.58 |
| 50-Day Moving Average | 0.90 |
| 20-Day Moving Average | 1.02 |
| 10-Day Moving Average | 1.07 |
| Average True Range | 0.12 |
| ADX | 35.44 |
| +DI | 29.05 |
| -DI | 12.74 |
| Chandelier Exit (Long, 3 ATRs ) | 1.03 |
| Chandelier Exit (Short, 3 ATRs ) | 1.15 |
| Upper Bollinger Band | 1.15 |
| Lower Bollinger Band | 0.89 |
| Percent B (%b) | 0.41 |
| BandWidth | 25.01 |
| MACD Line | 0.03 |
| MACD Signal Line | 0.04 |
| MACD Histogram | -0.007 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 1.08 | ||||
| Resistance 3 (R3) | 1.08 | 1.06 | 1.07 | ||
| Resistance 2 (R2) | 1.06 | 1.04 | 1.06 | 1.06 | |
| Resistance 1 (R1) | 1.03 | 1.02 | 1.01 | 1.03 | 1.06 |
| Pivot Point | 1.00 | 1.00 | 0.99 | 1.00 | 1.00 |
| Support 1 (S1) | 0.97 | 0.98 | 0.96 | 0.97 | 0.94 |
| Support 2 (S2) | 0.95 | 0.97 | 0.95 | 0.93 | |
| Support 3 (S3) | 0.92 | 0.95 | 0.93 | ||
| Support 4 (S4) | 0.92 |
